Evidence map›Paper›PMID 30288350›Full record

ArticleOncoimmunology

EBV infection determines the immune hallmarks of plasmablastic lymphoma.

Pauline Gravelle, Sarah Péricart, Marie Tosolini, Bettina Fabiani, Paul Coppo, Nadia Amara, Alexandra Traverse-Gléhen, Nathalie Van Acker, Pierre Brousset, Jean-Jacques Fournie and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.3field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Plasmablastic Lymphoma. A State-of-the-Art Review: Part 2-Focus on Therapy.Mediterranean journal of hematology and infectious diseases · 2024
    Review
  8. Article
  9. Plasmablastic lymphoma: An update.International journal of laboratory hematology · 2022
    Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Pauline GravelleDépartement de Pathologie, Institut Universitaire du Cancer-Oncopole, CHU Toulouse, Toulouse, France.
Sarah PéricartDépartement de Pathologie, Institut Universitaire du Cancer-Oncopole, CHU Toulouse, Toulouse, France.
Marie TosoliniINSERM, UMR 1037, Centre de Recherches en Cancérologie de Toulouse-Purpan, Toulouse, France.ORCID 0000-0001-5278-5952
Bettina FabianiDépartement de Pathologie, AP-HP, Hôpital Saint-Antoine, Paris, France.ORCID 0000-0003-1865-2587
Paul CoppoService d'Hématologie, AP-HP, Hôpital Saint-Antoine, Paris, France.
Nadia AmaraDépartement de Pathologie, Institut Universitaire du Cancer-Oncopole, CHU Toulouse, Toulouse, France.
Alexandra Traverse-GléhenFaculté de Médecine et de Maïeutique Lyon-Sud Charles Mérieux, Cancer Research Center of Lyon, INSERM 1052 CNRS 5286, Team "Clinical and Experimental Models of Lymphomagenesis", Oulins, France.
Nathalie Van AckerDépartement de Pathologie, Institut Universitaire du Cancer-Oncopole, CHU Toulouse, Toulouse, France.
Pierre BroussetDépartement de Pathologie, Institut Universitaire du Cancer-Oncopole, CHU Toulouse, Toulouse, France.
Jean-Jacques FournieINSERM, UMR 1037, Centre de Recherches en Cancérologie de Toulouse-Purpan, Toulouse, France.ORCID 0000-0001-6542-6908
Camille LaurentDépartement de Pathologie, Institut Universitaire du Cancer-Oncopole, CHU Toulouse, Toulouse, France.
Inserm · FRInstitut universitaire du cancer de Toulouse Oncopole · FRUniversité Toulouse III - Paul Sabatier · FRCentre National de la Recherche Scientifique · FRSorbonne Université · FRUniversité Claude Bernard Lyon 1 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite recent therapeutic progress, plasmablastic lymphoma (PBL), a distinct entity of high grade B cell lymphoma, is still an aggressive lymphoma with adverse prognosis. PBL commonly occurs in patients with HIV infection and PBL cells frequently express Epstein Barr virus (EBV) genome with type I latency. Occasionally however, PBL may develop in patients with an immunodepressed status without EBV and HIV infection. The aim of this study was to determine which PBL patients may benefit from the emerging strategies of immune checkpoint blockade. Here, we produced and analyzed the transcriptomic profiles of such tumors to address this question. Unsupervised hierarchical clustering analysis of PBL samples revealed they segregate according to their tumor EBV-status. Moreover, EBV

Indexed as

deep deconvolutionEpstein-Barr virusgene expression profileimmune checkpointsimmune escapemultiplex immunofluorescencePlasmablastic lymphoma

Identifiers

PMID30288350
PMCPMC6169584
OpenAlexW2886222140

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.